Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

New deal for Oncurious, VIB
10-11-2017
SHARING OPTIONS:

LEUVEN, Belgium—Biotech company Oncurious NV shared news in September of a principle agreement with VIB for the acquisition of exclusive licenses to a portfolio of five next-generation immuno-oncology assets. The assets are based on work from the VIB-KU Leuven labs of Massimiliano Mazzone and Gabriele Bergers, and from the VIB-VUB lab of Jo Van Ginderachter. VIB Discovery Sciences will serve as lead for preclinical development of the new projects, and as part of the deal, will increase its stake in Oncurious. VIB also stands to receive a royalty on future sales of any assets related to the deal. In addition, ThromboGenics, which remains Oncurious’ majority shareholder, has invested a further €2.1 million in the company.
Oncurious Executive Chairman Dr. Patrik De Haes said, “This new collaboration with VIB and the resulting portfolio propels Oncurious into the very exciting area of immuno-oncology, with a focus on next-generation therapies. We are very privileged to have the world-class VIB team as our venture partner.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.